This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Agence fédérale des médicaments et des produits de santé | |
|---|---|
| Name | Agence fédérale des médicaments et des produits de santé |
| Native name | Agence fédérale des médicaments et des produits de santé |
| Formed | 2007 |
| Jurisdiction | Belgium |
| Headquarters | Brussels |
| Chief1 name | (Director-general) |
Agence fédérale des médicaments et des produits de santé is the federal regulatory authority responsible for the evaluation, authorization and supervision of pharmaceuticals and medical devices in Belgium. It operates within the Belgian federal administration and interacts with European Union, World Health Organization and pharmaceutical industry stakeholders to ensure public health protection. The agency's work touches on regulatory science, pharmacovigilance, clinical research oversight and market surveillance across Belgian territory including Brussels and Wallonia.
The agency was established through Belgian administrative reforms influenced by precedents such as European Medicines Agency, Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, and reforms following incidents like the Porphyria scandal in European pharmaceutical policy debates. Its creation in 2007 followed legal frameworks shaped by the European Union directives on medicinal products and by national statutes promulgated in Brussels and adopted by the Belgian Federal Parliament. Over time, its evolution mirrored milestones such as revisions to the Clinical Trials Regulation, coordination with the Pharmacopoeia networks, and responses to crises including the COVID-19 pandemic, which required intensified cooperation with agencies like the European Centre for Disease Prevention and Control and the World Health Organization.
The agency's mandate derives from Belgian laws and implements instruments aligned with the European Medicines Agency guidelines and European Commission regulations. Its responsibilities include marketing authorization evaluations similar to processes at the Food and Drug Administration and the Medicines and Healthcare products Regulatory Agency, pharmacovigilance functions comparable to those in World Health Organization programs, and oversight of manufacturing practices informed by Good Manufacturing Practice standards adopted across the European Union. It enforces national legislation enacted by the Belgian Federal Parliament and collaborates with regional administrations in Flanders and Wallonia on public health interventions.
The agency's governance comprises a director-general, advisory boards, scientific committees, and inspectorates that interact with institutions such as the Belgian Superior Health Council and academic partners including Université catholique de Louvain, Université libre de Bruxelles, Ghent University, and Université de Liège. Its scientific committees draw expertise from specialists who have served on panels for the European Medicines Agency, the World Health Organization, and national regulatory bodies such as the Agence nationale de sécurité du médicament et des produits de santé and the Paul-Ehrlich-Institut. Oversight mechanisms involve reporting to ministers within the Belgian Federal Government and engagement with parliamentary committees of the Belgian Federal Parliament.
The agency conducts marketing authorization procedures, benefit–risk assessments, post-marketing surveillance, and regulatory inspections. It evaluates clinical trial applications in coordination with ethics committees like those at CHU Saint-Pierre and hospitals such as Cliniques universitaires Saint-Luc and UZ Leuven. Its functions include issuing guidelines on pharmacovigilance akin to those issued by the European Medicines Agency, managing adverse event reporting systems used by healthcare institutions such as AZ Sint-Jan and OLV Ziekenhuis, and coordinating recall actions with law enforcement agencies and consumer protection bodies like the Belgian Competition and Consumer Commission.
The agency assesses human and veterinary medicinal products and medical devices under frameworks derived from European Union directives and regulations including the Medical Device Regulation (EU) 2017/745 and the Clinical Trials Regulation (EU) No 536/2014. It liaises with notified bodies, manufacturers such as multinational firms headquartered in Belgium and across Europe, and research organisations including Institut Pasteur and VIB. The agency engages in conformity assessment, labeling oversight, and evidence review practices informed by standards from organisations like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the European Directorate for the Quality of Medicines & HealthCare.
Inspectional activities cover Good Manufacturing Practice inspections, market surveillance of pharmacies and distributors like Brantano and hospital supply chains in institutions such as CHU de Charleroi. The agency runs pharmacovigilance databases and collaborates with the Belgian Centre for Pharmacoepidemiology and academic pharmacoepidemiology groups at KU Leuven to detect safety signals. In public health emergencies it coordinates with the Federal Public Service Health, Food Chain Safety and Environment, the Belgian Civil Protection, and international partners including the European Centre for Disease Prevention and Control to manage recalls, lot withdrawals and risk communication campaigns.
Nationally, the agency interfaces with regional health authorities in Brussels, Flanders, and Wallonia, with hospital networks such as UZ Gent and CHU Liège, and with professional bodies like the Belgian Order of Pharmacists. Internationally, it maintains working relationships with the European Medicines Agency, regulatory counterparts including the Food and Drug Administration, Health Canada, and the Therapeutic Goods Administration, and participates in international fora such as International Coalition of Medicines Regulatory Authorities and World Health Organization expert committees. These partnerships support harmonisation of regulatory standards, mutual recognition agreements, and coordinated responses to transnational public health threats.
Category:Pharmaceutical regulatory agencies Category:Health organisations based in Belgium